BACKGROUND & AIMS: Widespread screening for colorectal cancer (CRC) has reduced its incidence and mortality. Previous studies investigated the economic effects of CRC screening. We performed a systematic review to provide up to date evidence of the cost effectiveness of CRC screening strategies by answering 3 research questions. METHODS: We searched PubMed, NHS EED, SSCI, EconLit, and 3 supplemental databases for original articles published in English from January 2010 through December 2017. All monetary values were converted to United States (US) dollars (year 2016). For all research questions, we extracted, or calculated (if necessary), per-person costs and life years (LY) and/or quality-adjusted LYs (QALY), as well as the incremental costs per LY gained or QALY gained compared to the baseline strategy. A cost-saving strategy is defined as one that was less costly and equally or more effective than the baseline strategy. Net monetary benefit approach was used to answer research question 2. RESULTS: Our review comprised 33 studies (17 from Europe, 11 from North America, 4 from Asia, and 1 from Australia). Annual and biennial guaiac-based fecal occult blood tests, annual and biennial fecal immunochemical tests, colonoscopy every 10 years, and flexible sigmoidoscopy every 5 years were cost-effective (even cost saving in most US models) compared with no screening. Additionally, colonoscopy every 10 years was less costly and/or more effective than other common strategies in the US. Newer strategies such as computed tomographic colonography, every 5 or 10 years, were cost-effective compared to no screening. CONCLUSION: In an updated review, we found that common CRC screening strategies and computed tomographic colonography continued to be cost-effective compared to no screening. There were discrepancies among studies from different regions, which could be associated with the model types or model assumptions.